<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="other" dtd-version="1.1d3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Med</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosmed</journal-id>
<journal-title-group>
<journal-title>PLOS Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1549-1277</issn>
<issn pub-type="epub">1549-1676</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pmed.1002205</article-id>
<article-id pub-id-type="publisher-id">PMEDICINE-D-16-03694</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Perspective</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Cancer detection and diagnosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer detection and diagnosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Signs and symptoms</subject><subj-group><subject>Lesions</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Signs and symptoms</subject><subj-group><subject>Lesions</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Lung and intrathoracic tumors</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Surgical and invasive medical procedures</subject><subj-group><subject>Biopsy</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pulmonology</subject><subj-group><subject>Chronic obstructive pulmonary disease</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Hematology</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Lung and intrathoracic tumors</subject><subj-group><subject>Small cell lung cancer</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Lung and intrathoracic tumors</subject><subj-group><subject>Secondary lung tumors</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Blood-Based Analysis of Circulating Cell-Free DNA and Tumor Cells for Early Cancer Detection</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Pantel</surname>
<given-names>Klaus</given-names>
</name>
<xref ref-type="corresp" rid="cor001">*</xref>
<xref ref-type="aff" rid="aff001"/>
</contrib>
</contrib-group>
<aff id="aff001"><addr-line>Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The author has declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">pantel@uke.de</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>27</day>
<month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<month>12</month>
<year>2016</year>
</pub-date>
<volume>13</volume>
<issue>12</issue>
<elocation-id>e1002205</elocation-id>
<permissions>
<copyright-year>2016</copyright-year>
<copyright-holder>Klaus Pantel</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pmed.1002205"/>
<abstract abstract-type="toc">
<p>In a Perspective, Klaus Pantel discusses prospects for use of cell-free DNA and circulating tumor cells in cancer detection.</p>
</abstract>
<funding-group>
<funding-statement>KP received support from CANCER-ID, an Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115749, resources of which are composed of financial contribution from the European Union’s Seventh Framework Program (FP7/2007-2013) and EFPIA companies’ in-kind contribution.</funding-statement>
</funding-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<page-count count="5"/>
</counts>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Analysis of circulating cell-free DNA (cfDNA) or circulating tumor cells (CTCs), also known as liquid biopsy, has received substantial attention in recent years owing to the potential benefits for detecting tumors and informing treatment [<xref ref-type="bibr" rid="pmed.1002205.ref001">1</xref>]. cfDNA is released into the blood by apoptotic and necrotic cells, and cancer patients have increased concentrations of cfDNA [<xref ref-type="bibr" rid="pmed.1002205.ref002">2</xref>]. CTCs are released by primary tumor lesions into the blood and eventually home to distant organs such as liver, bone, lungs, or brain. Building on groundbreaking work by Kinzler, Vogelstein, and colleages [<xref ref-type="bibr" rid="pmed.1002205.ref003">3</xref>], novel technologies now enable detection of tumor-associated mutations in cfDNA. The choice of cfDNA sequencing technology depends on the fraction of circulating tumor-derived DNA (ctDNA) within the pool of cfDNA, which is usually much higher (&gt;5%–10%) in patients with advanced disease compared to patients at earlier disease stages (&lt;1%) [<xref ref-type="bibr" rid="pmed.1002205.ref004">4</xref>,<xref ref-type="bibr" rid="pmed.1002205.ref005">5</xref>]. Technologies that can detect minute amounts of ctDNA have been developed, but these require proof-reading measures to avoid artefacts [<xref ref-type="bibr" rid="pmed.1002205.ref006">6</xref>]. Genomic analyses of single CTCs require whole genome amplification to obtain sufficient amounts of DNA, which needs to be controlled well to minimize bias [<xref ref-type="bibr" rid="pmed.1002205.ref007">7</xref>]. Consequently, the detection of very low amounts of ctDNA and CTCs in blood samples from early-stage cancer patients, and assessment of the possible clinical significance of the resulting findings, is still a challenge [<xref ref-type="bibr" rid="pmed.1002205.ref004">4</xref>,<xref ref-type="bibr" rid="pmed.1002205.ref005">5</xref>].</p>
<p>Besides CTCs and ctDNA, liquid biopsy analyses can also focus on microvesicles (particularly exosomes), cell-free microRNAs, and blood platelets, which also provide interesting information on molecular features of a tumor lesion and might, therefore, have the potential to contribute to early detection of cancer [<xref ref-type="bibr" rid="pmed.1002205.ref008">8</xref>–<xref ref-type="bibr" rid="pmed.1002205.ref010">10</xref>]. Moreover, like CTCs, exosomes are biomarkers with a biological function in metastatic development [<xref ref-type="bibr" rid="pmed.1002205.ref011">11</xref>]. However, the present discussion focuses on CTCs and ctDNA, which are currently the most prominent targets of liquid biopsy analyses in cancer patients.</p>
</sec>
<sec id="sec002">
<title>cfDNA in Patients with Early-Stage Cancer</title>
<p>As an example, Fernandez-Cuesta and colleagues [<xref ref-type="bibr" rid="pmed.1002205.ref012">12</xref>] recently used a pipeline specifically designed to accurately detect sequence variants present at very low fractions in cfDNA from patients with small-cell lung cancer (SCLC), addressing TP53 mutations, which are known to occur in the majority of cases of SCLC [<xref ref-type="bibr" rid="pmed.1002205.ref013">13</xref>]. TP53 mutations were detected in only 35.7% of early-stage cases, indicating limited sensitivity as marker for detection of early SCLC. More sensitive technologies or the addition of other cancer-specific mutations, or combinations thereof, might in the future be able to increase the sensitivity of liquid biopsy in this type of setting. Moreover, quite large plasma volumes could be required for early cancer detection, because the ctDNA concentration in early-stage lung cancer patients can be as low as one genome equivalent in 5 ml blood [<xref ref-type="bibr" rid="pmed.1002205.ref006">6</xref>]. Bettegowda and coworkers used digital PCR-based technologies to evaluate the usefulness of ctDNA for detection of tumors in 640 patients with various cancer types [<xref ref-type="bibr" rid="pmed.1002205.ref004">4</xref>]—ctDNA was detected in only 48%–73% of patients with localized colorectal cancer, gastroesophageal cancer, pancreatic cancer, and breast adenocarcinoma. Again, these detection rates are not satisfactory for early cancer detection because false negative determinations are likely to be common.</p>
</sec>
<sec id="sec003">
<title>Cancer-Associated Mutations in Cancer-Free Individuals</title>
<p>In addition to the need for higher sensitivity, the specificity of cfDNA measurements also faces serious challenges. Recent reports have shown that cancer-associated mutations are not restricted to cancer patients. For example, TP53-mutated cfDNA fragments were observed in 11.4% of 123 matched noncancer controls [<xref ref-type="bibr" rid="pmed.1002205.ref012">12</xref>], and Krimmel and colleagues demonstrated very low levels of TP53 mutations in the peritoneal fluid and peripheral blood of women with benign ovarian lesions [<xref ref-type="bibr" rid="pmed.1002205.ref014">14</xref>]. Likewise, leukemia-associated mutations have been shown to occur with increasing age and, although such mutations pose a statistically significant risk for a person to develop leukemia, most individuals (&gt;90%) with these mutations never developed leukemia during their lifetime [<xref ref-type="bibr" rid="pmed.1002205.ref015">15</xref>]. Because the presence of cancer-associated mutations in cfDNA might not necessarily indicate that the individual tested has cancer or will develop cancer, the risk of substantial anxiety for patients and unnecessary medical interventions is substantial.</p>
<p>The findings of such studies appear to reflect general principles that challenge the promise of ctDNA analysis for early cancer detection. Genomic alterations, such as those in the <italic>BRAF</italic>, <italic>RAS</italic>, <italic>EGFR</italic>, <italic>HER2</italic>, <italic>FGFR3</italic>, <italic>PIK3CA</italic>, <italic>TP53</italic>, <italic>CDKN2A</italic>, and <italic>NF1/2</italic> genes, all of which are considered hallmark drivers of specific cancers, can also be identified in benign and premalignant conditions, occasionally at frequencies higher than in their malignant counterparts [<xref ref-type="bibr" rid="pmed.1002205.ref016">16</xref>]. For example, <italic>BRAF</italic> V600E mutations are paradoxically more frequent in benign nevi (∼80%) than in dysplastic nevi (∼60%) or melanomas (∼40%–45%) [<xref ref-type="bibr" rid="pmed.1002205.ref017">17</xref>]. Driver mutations also occur in nonmalignant conditions, such as <italic>FGFR3</italic> mutations in seborrheic keratosis [<xref ref-type="bibr" rid="pmed.1002205.ref018">18</xref>].</p>
</sec>
<sec id="sec004">
<title>CTCs for Early Detection of Cancer</title>
<p>Cancer patients harbor CTCs in their bloodstream that can be detected at very low concentrations using advanced technologies [<xref ref-type="bibr" rid="pmed.1002205.ref019">19</xref>]. After an enrichment step that increases the concentration of CTCs by several log units, CTCs can be positively or negatively enriched on the basis of biological properties (i.e., expression of protein markers) or on the basis of physical properties (i.e., size, density, deformability, or electric charge) [<xref ref-type="bibr" rid="pmed.1002205.ref019">19</xref>]. Positive or negative CTC enrichment can also be combined in the same device. CTCs are released early during tumor development and have been found in patients with small primary tumors (e.g., breast cancer) [<xref ref-type="bibr" rid="pmed.1002205.ref020">20</xref>]. Thus, detection of CTCs rather than cfDNA might be an alternative approach to early cancer identification. In patients with chronic obstructive pulmonary disease (COPD) who have an elevated risk of developing lung cancer, Ilie and colleagues reported that CTCs could be detected in 3% of COPD patients [<xref ref-type="bibr" rid="pmed.1002205.ref021">21</xref>]. Annual surveillance of CTC-positive COPD patients by CT screening detected lung nodules one to four years after CTC detection, leading to prompt surgical resection and histopathological diagnosis of early-stage lung cancer, while no CTCs were detected in control smoking and nonsmoking individuals with normal lung function. These encouraging preliminary findings need to be validated in larger cohorts and other tumor types with similar conditions conferring an increased risk of cancer.</p>
</sec>
<sec id="sec005">
<title>Current Challenges of cfDNA Analyses</title>
<p>Achieving acceptable levels of sensitivity and specificity for early cancer detection will require further technical advances. Extensive research is required to identify possible combinations of cancer-specific mutations and define potential quantitative thresholds to avoid overdiagnosis. Based on the findings to date, it can already be envisaged that DNA sequencing needs to be broad, so as to encompass considerable tumor heterogeneity, and deep, to detect minute amounts of ctDNA fragments in the milieu of extensive genetically normal cfDNA. Nonmalignant conditions that can lead to the death of normal cells may also lead to a further dilution of ctDNA molecules and hamper quantitative evaluations. Very sensitive technologies that allow the detection of less than 0.1% of ctDNA in blood plasma (e.g., digital droplet PCR or cancer personalized profiling [CAPP] by deep sequencing methods) have been developed and applied to cfDNA analyses in patients with various forms of cancer [<xref ref-type="bibr" rid="pmed.1002205.ref004">4</xref>,<xref ref-type="bibr" rid="pmed.1002205.ref006">6</xref>,<xref ref-type="bibr" rid="pmed.1002205.ref022">22</xref>], but the key biological limitation might be the number of genome equivalents present in blood samples from early-stage cancer patients [<xref ref-type="bibr" rid="pmed.1002205.ref005">5</xref>].</p>
</sec>
<sec id="sec006">
<title>Current Challenges of CTC Analyses</title>
<p>The potential use of CTCs for early cancer detection faces similar challenges of sensitivity and specificity. DNA sequencing of single CTCs has been successfully performed by several groups, but the whole genome step required to obtain sufficient amounts of DNA requires standardization [<xref ref-type="bibr" rid="pmed.1002205.ref007">7</xref>]. RNA sequencing of CTCs has also become possible [<xref ref-type="bibr" rid="pmed.1002205.ref023">23</xref>], but this approach requires rapid CTC capture technologies to avoid RNA degradation. Moreover, the analysis of larger blood volumes might be required to obtain sufficient amounts of CTCs, which is a limitation for a cancer screening method. Conditions that may lead to nonspecific findings in noncancer patients, such as the release of epithelial cells into the bloodstream of patients with inflammatory bowel diseases [<xref ref-type="bibr" rid="pmed.1002205.ref024">24</xref>], need to be explored to avoid false positives. Nevertheless, CTC capture should also permit functional studies in xenograft models [<xref ref-type="bibr" rid="pmed.1002205.ref025">25</xref>,<xref ref-type="bibr" rid="pmed.1002205.ref026">26</xref>] and the development of cell lines as models for in-depth investigation of CTC biology and drug testing [<xref ref-type="bibr" rid="pmed.1002205.ref027">27</xref>].</p>
</sec>
<sec id="sec007">
<title>Conclusion and Perspectives</title>
<p>Studies evaluating new approaches to early cancer detection usually begin with comparisons of small cohorts of cancer patients with controls (healthy individuals or patients with benign diseases). Subsequent investigations will typically involve larger study populations and extended follow-up times and require substantial financial resources. Focusing on population groups at an elevated risk of developing cancer (e.g., COPD patients or patients with a well-known genetic predisposition to breast or colon cancer) is a good strategy to speed up the process of testing and validation of new approaches and technologies. In contrast, large population-based screening efforts may reveal tumor lesions that cannot generally be cured by current therapies (e.g., pancreatic cancer) or that have an indolent disease course in many patients (e.g., prostate or thyroid cancer) and where the need for therapy is not clear.</p>
<p>Another important clinical application is early detection of minimal residual disease (MRD) in patients with resected primary tumors. Postsurgical surveillance of MRD by cfDNA analysis has enabled investigation of clonal evolution in colorectal cancer patients [<xref ref-type="bibr" rid="pmed.1002205.ref022">22</xref>,<xref ref-type="bibr" rid="pmed.1002205.ref028">28</xref>]. Current clinical trials are focusing on stratification and monitoring of therapies in cancer patients using CTC or cfDNA analyses. For example, in breast cancer, the METABREAST trial is assessing whether CTC counts are helpful in the decision about whether chemotherapy or less aggressive endocrine therapy is needed, while the DETECT-III trial is evaluating whether patients with HER2-negative primary tumors but HER2-positive CTCs will profit from anti-HER2 therapy with lapatinib [<xref ref-type="bibr" rid="pmed.1002205.ref029">29</xref>]. Regarding the use of cfDNA for early cancer detection, enormous resources are required to identify genomic aberrations specific and sensitive enough to detect early malignant lesions in large cohort studies.</p>
<p>Finally, verification of the findings of approaches involving liquid biopsy will call for acquisition of information on the putative location of the occult lesion to select the appropriate imaging modalities or other diagnostic means prior to planning appropriate therapies. In this context, the detection of tissue-specific gene expression in CTCs [<xref ref-type="bibr" rid="pmed.1002205.ref030">30</xref>] might be a promising approach.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other" id="fn001">
<p><bold>Provenance:</bold> Commissioned; not externally-peer reviewed.</p>
</fn>
</fn-group>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item><term>CAPP</term>
<def><p>cancer personalized profiling</p></def>
</def-item>
<def-item><term>cfDNA</term>
<def><p>circulating cell-free DNA</p></def>
</def-item>
<def-item><term>COPD</term>
<def><p>chronic obstructive pulmonary disease</p></def>
</def-item>
<def-item><term>CTC</term>
<def><p>circulating tumor cell</p></def>
</def-item>
<def-item><term>ctDNA</term>
<def><p>circulating tumor-derived DNA</p></def>
</def-item>
<def-item><term>MRD</term>
<def><p>minimal residual disease</p></def>
</def-item>
<def-item><term>SCLC</term>
<def><p>small-cell lung cancer</p></def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="pmed.1002205.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alix-Panabieres</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Pantel</surname> <given-names>K</given-names></name>. <article-title>Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy</article-title>. <source>Cancer Discov</source>. <year>2016</year>;<volume>6</volume>(<issue>5</issue>):<fpage>479</fpage>–<lpage>91</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/2159-8290.CD-15-1483" xlink:type="simple">10.1158/2159-8290.CD-15-1483</ext-link></comment> <object-id pub-id-type="pmid">26969689</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schwarzenbach</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Hoon</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Pantel</surname> <given-names>K</given-names></name>. <article-title>Cell-free nucleic acids as biomarkers in cancer patients</article-title>. <source>Nat Rev Cancer</source>. <year>2011</year>;<volume>11</volume>(<issue>6</issue>):<fpage>426</fpage>–<lpage>37</lpage>. Epub 2011/05/13. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrc3066" xlink:type="simple">10.1038/nrc3066</ext-link></comment> <object-id pub-id-type="pmid">21562580</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Diehl</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Schmidt</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Choti</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Romans</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Goodman</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Circulating mutant DNA to assess tumor dynamics</article-title>. <source>Nat Med</source>. <year>2008</year>;<volume>14</volume>(<issue>9</issue>):<fpage>985</fpage>–<lpage>90</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nm.1789" xlink:type="simple">10.1038/nm.1789</ext-link></comment> <object-id pub-id-type="pmid">18670422</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bettegowda</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Sausen</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Leary</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Kinde</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Agrawal</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Detection of circulating tumor DNA in early- and late-stage human malignancies</article-title>. <source>Sci Transl Med</source>. <year>2014</year>;<volume>6</volume>(<issue>224</issue>):<fpage>224ra24</fpage>. Epub 2014/02/21. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/scitranslmed.3007094" xlink:type="simple">10.1126/scitranslmed.3007094</ext-link></comment> <object-id pub-id-type="pmid">24553385</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Newman</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Bratman</surname> <given-names>SV</given-names></name>, <name name-style="western"><surname>To</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wynne</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Eclov</surname> <given-names>NC</given-names></name>, <name name-style="western"><surname>Modlin</surname> <given-names>LA</given-names></name>, <etal>et al</etal>. <article-title>An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage</article-title>. <source>Nat Med</source>. <year>2014</year>;<volume>20</volume>(<issue>5</issue>):<fpage>548</fpage>–<lpage>54</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nm.3519" xlink:type="simple">10.1038/nm.3519</ext-link></comment> <object-id pub-id-type="pmid">24705333</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Newman</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Lovejoy</surname> <given-names>AF</given-names></name>, <name name-style="western"><surname>Klass</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Kurtz</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Chabon</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Scherer</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Integrated digital error suppression for improved detection of circulating tumor DNA</article-title>. <source>Nat Biotechnol</source>. <year>2016</year>;<volume>34</volume>(<issue>5</issue>):<fpage>547</fpage>–<lpage>55</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nbt.3520" xlink:type="simple">10.1038/nbt.3520</ext-link></comment> <object-id pub-id-type="pmid">27018799</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Babayan</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Alawi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Gormley</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Muller</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Wikman</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>McMullin</surname> <given-names>RP</given-names></name>, <etal>et al</etal>. <article-title>Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells</article-title>. <source>Oncotarget</source>. <year>2016</year>.</mixed-citation></ref>
<ref id="pmed.1002205.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schwarzenbach</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Nishida</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Calin</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Pantel</surname> <given-names>K</given-names></name>. <article-title>Clinical relevance of circulating cell-free microRNAs in cancer</article-title>. <source>Nat Rev Clin Oncol</source>. <year>2014</year>;<volume>11</volume>(<issue>3</issue>):<fpage>145</fpage>–<lpage>56</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrclinonc.2014.5" xlink:type="simple">10.1038/nrclinonc.2014.5</ext-link></comment> <object-id pub-id-type="pmid">24492836</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Best</surname> <given-names>MG</given-names></name>, <name name-style="western"><surname>Sol</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Kooi</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Tannous</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Westerman</surname> <given-names>BA</given-names></name>, <name name-style="western"><surname>Rustenburg</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics</article-title>. <source>Cancer Cell</source>. <year>2015</year>;<volume>28</volume>(<issue>5</issue>):<fpage>666</fpage>–<lpage>76</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ccell.2015.09.018" xlink:type="simple">10.1016/j.ccell.2015.09.018</ext-link></comment> <object-id pub-id-type="pmid">26525104</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Melo</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Luecke</surname> <given-names>LB</given-names></name>, <name name-style="western"><surname>Kahlert</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Fernandez</surname> <given-names>AF</given-names></name>, <name name-style="western"><surname>Gammon</surname> <given-names>ST</given-names></name>, <name name-style="western"><surname>Kaye</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Glypican-1 identifies cancer exosomes and detects early pancreatic cancer</article-title>. <source>Nature</source>. <year>2015</year>;<volume>523</volume>(<issue>7559</issue>):<fpage>177</fpage>–<lpage>82</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature14581" xlink:type="simple">10.1038/nature14581</ext-link></comment> <object-id pub-id-type="pmid">26106858</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hoshino</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Costa-Silva</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Shen</surname> <given-names>TL</given-names></name>, <name name-style="western"><surname>Rodrigues</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Hashimoto</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tesic Mark</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Tumour exosome integrins determine organotropic metastasis</article-title>. <source>Nature</source>. <year>2015</year>;<volume>527</volume>(<issue>7578</issue>):<fpage>329</fpage>–<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature15756" xlink:type="simple">10.1038/nature15756</ext-link></comment> <object-id pub-id-type="pmid">26524530</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fernandez-Cuesta</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Perdomo</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Avogbe</surname> <given-names>PH</given-names></name>, <name name-style="western"><surname>Leblay</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Delhomme</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Gaborieau</surname> <given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer</article-title>. <source>EBioMedicine</source>. <year>2016</year>;<volume>10</volume>:<fpage>117</fpage>–<lpage>23</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ebiom.2016.06.032" xlink:type="simple">10.1016/j.ebiom.2016.06.032</ext-link></comment> <object-id pub-id-type="pmid">27377626</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>George</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Lim</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Jang</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Cun</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Ozretic</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Kong</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Comprehensive genomic profiles of small cell lung cancer</article-title>. <source>Nature</source>. <year>2015</year>;<volume>524</volume>(<issue>7563</issue>):<fpage>47</fpage>–<lpage>53</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature14664" xlink:type="simple">10.1038/nature14664</ext-link></comment> <object-id pub-id-type="pmid">26168399</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Krimmel</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Schmitt</surname> <given-names>MW</given-names></name>, <name name-style="western"><surname>Harrell</surname> <given-names>MI</given-names></name>, <name name-style="western"><surname>Agnew</surname> <given-names>KJ</given-names></name>, <name name-style="western"><surname>Kennedy</surname> <given-names>SR</given-names></name>, <name name-style="western"><surname>Emond</surname> <given-names>MJ</given-names></name>, <etal>et al</etal>. <article-title>Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2016</year>;<volume>113</volume>(<issue>21</issue>):<fpage>6005</fpage>–<lpage>10</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.1601311113" xlink:type="simple">10.1073/pnas.1601311113</ext-link></comment> <object-id pub-id-type="pmid">27152024</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Genovese</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Kahler</surname> <given-names>AK</given-names></name>, <name name-style="western"><surname>Handsaker</surname> <given-names>RE</given-names></name>, <name name-style="western"><surname>Lindberg</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Rose</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Bakhoum</surname> <given-names>SF</given-names></name>, <etal>et al</etal>. <article-title>Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>371</volume>(<issue>26</issue>):<fpage>2477</fpage>–<lpage>87</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa1409405" xlink:type="simple">10.1056/NEJMoa1409405</ext-link></comment> <object-id pub-id-type="pmid">25426838</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kato</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Lippman</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Flaherty</surname> <given-names>KT</given-names></name>, <name name-style="western"><surname>Kurzrock</surname> <given-names>R</given-names></name>. <article-title>The Conundrum of Genetic "Drivers" in Benign Conditions</article-title>. <source>J Natl Cancer Inst</source>. <year>2016</year>;<volume>108</volume>(<issue>8</issue>).</mixed-citation></ref>
<ref id="pmed.1002205.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pollock</surname> <given-names>PM</given-names></name>, <name name-style="western"><surname>Harper</surname> <given-names>UL</given-names></name>, <name name-style="western"><surname>Hansen</surname> <given-names>KS</given-names></name>, <name name-style="western"><surname>Yudt</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Stark</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Robbins</surname> <given-names>CM</given-names></name>, <etal>et al</etal>. <article-title>High frequency of BRAF mutations in nevi</article-title>. <source>Nat Genet</source>. <year>2003</year>;<volume>33</volume>(<issue>1</issue>):<fpage>19</fpage>–<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng1054" xlink:type="simple">10.1038/ng1054</ext-link></comment> <object-id pub-id-type="pmid">12447372</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hafner</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>van Oers</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Hartmann</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Landthaler</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Stoehr</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Blaszyk</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>High frequency of FGFR3 mutations in adenoid seborrheic keratoses</article-title>. <source>J Invest Dermatol</source>. <year>2006</year>;<volume>126</volume>(<issue>11</issue>):<fpage>2404</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/sj.jid.5700422" xlink:type="simple">10.1038/sj.jid.5700422</ext-link></comment> <object-id pub-id-type="pmid">16778799</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alix-Panabieres</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Pantel</surname> <given-names>K</given-names></name>. <article-title>Challenges in circulating tumour cell research</article-title>. <source>Nat Rev Cancer</source>. <year>2014</year>;<volume>14</volume>(<issue>9</issue>):<fpage>623</fpage>–<lpage>31</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrc3820" xlink:type="simple">10.1038/nrc3820</ext-link></comment> <object-id pub-id-type="pmid">25154812</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rack</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Schindlbeck</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Juckstock</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Andergassen</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Hepp</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Zwingers</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Circulating tumor cells predict survival in early average-to-high risk breast cancer patients</article-title>. <source>J Natl Cancer Inst</source>. <year>2014</year>;<volume>106</volume>(<issue>5</issue>).</mixed-citation></ref>
<ref id="pmed.1002205.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ilie</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Hofman</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Long-Mira</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Selva</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Vignaud</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Padovani</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>"Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease</article-title>. <source>PLoS ONE</source>. <year>2014</year>;<volume>9</volume>(<issue>10</issue>):<fpage>e111597</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0111597" xlink:type="simple">10.1371/journal.pone.0111597</ext-link></comment> <object-id pub-id-type="pmid">25360587</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tie</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Tomasetti</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Springer</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kinde</surname> <given-names>I</given-names></name>, <etal>et al</etal>. <article-title>Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer</article-title>. <source>Sci Transl Med</source>. <year>2016</year>;<volume>8</volume>(<issue>346</issue>):<fpage>346ra92</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/scitranslmed.aaf6219" xlink:type="simple">10.1126/scitranslmed.aaf6219</ext-link></comment> <object-id pub-id-type="pmid">27384348</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jordan</surname> <given-names>NV</given-names></name>, <name name-style="western"><surname>Bardia</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Wittner</surname> <given-names>BS</given-names></name>, <name name-style="western"><surname>Benes</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Ligorio</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Zheng</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>HER2 expression identifies dynamic functional states within circulating breast cancer cells</article-title>. <source>Nature</source>. <year>2016</year>;<volume>537</volume>(<issue>7618</issue>):<fpage>102</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature19328" xlink:type="simple">10.1038/nature19328</ext-link></comment> <object-id pub-id-type="pmid">27556950</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pantel</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Deneve</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Nocca</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Coffy</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Vendrell</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Maudelonde</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Circulating epithelial cells in patients with benign colon diseases</article-title>. <source>Clin Chem</source>. <year>2012</year>;<volume>58</volume>(<issue>5</issue>):<fpage>936</fpage>–<lpage>40</lpage>. Epub 2011/12/30. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1373/clinchem.2011.175570" xlink:type="simple">10.1373/clinchem.2011.175570</ext-link></comment> <object-id pub-id-type="pmid">22205690</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Baccelli</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Schneeweiss</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Riethdorf</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Stenzinger</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Schillert</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Vogel</surname> <given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay</article-title>. <source>Nat Biotechnol</source>. <year>2013</year>;<volume>31</volume>(<issue>6</issue>):<fpage>539</fpage>–<lpage>44</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nbt.2576" xlink:type="simple">10.1038/nbt.2576</ext-link></comment> <object-id pub-id-type="pmid">23609047</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hodgkinson</surname> <given-names>CL</given-names></name>, <name name-style="western"><surname>Morrow</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Metcalf</surname> <given-names>RL</given-names></name>, <name name-style="western"><surname>Rothwell</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Trapani</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer</article-title>. <source>Nat Med</source>. <year>2014</year>;<volume>20</volume>(<issue>8</issue>):<fpage>897</fpage>–<lpage>903</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nm.3600" xlink:type="simple">10.1038/nm.3600</ext-link></comment> <object-id pub-id-type="pmid">24880617</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cayrefourcq</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Mazard</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Joosse</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Solassol</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ramos</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Assenat</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Establishment and characterization of a cell line from human circulating colon cancer cells</article-title>. <source>Cancer Res</source>. <year>2015</year>;<volume>75</volume>(<issue>5</issue>):<fpage>892</fpage>–<lpage>901</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/0008-5472.CAN-14-2613" xlink:type="simple">10.1158/0008-5472.CAN-14-2613</ext-link></comment> <object-id pub-id-type="pmid">25592149</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Siravegna</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Mussolin</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Buscarino</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Corti</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Cassingena</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Crisafulli</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients</article-title>. <source>Nat Med</source>. <year>2015</year>;<volume>21</volume>(<issue>7</issue>):<fpage>827</fpage>.</mixed-citation></ref>
<ref id="pmed.1002205.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bidard</surname> <given-names>FC</given-names></name>, <name name-style="western"><surname>Fehm</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Ignatiadis</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Smerage</surname> <given-names>JB</given-names></name>, <name name-style="western"><surname>Alix-Panabieres</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Janni</surname> <given-names>W</given-names></name>, <etal>et al</etal>. <article-title>Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials</article-title>. <source>Cancer Metastasis Rev</source>. <year>2013</year>;<volume>32</volume>(<issue>1–2</issue>):<fpage>179</fpage>–<lpage>88</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10555-012-9398-0" xlink:type="simple">10.1007/s10555-012-9398-0</ext-link></comment> <object-id pub-id-type="pmid">23129208</object-id></mixed-citation></ref>
<ref id="pmed.1002205.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gorges</surname> <given-names>TM</given-names></name>, <name name-style="western"><surname>Kuske</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Rock</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Mauermann</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Muller</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Peine</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells</article-title>. <source>Clin Chem</source>. <year>2016</year>; <volume>62</volume>(<issue>11</issue>):<fpage>1504</fpage>–<lpage>15</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1373/clinchem.2016.260299" xlink:type="simple">10.1373/clinchem.2016.260299</ext-link></comment> <object-id pub-id-type="pmid">27630154</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>